Medicine shortage communication (MSC): TEGSEDI® (inotersen sodium, 284 mg solution for injection in prefilled syringe): planned marketing cessation (discontinuation)

Submitted by Anonymous (not verified) on 3 July 2026 - 8:16

Medicine shortage communication (MSC): TEGSEDI® (inotersen sodium, 284 mg solution for injection in prefilled syringe): planned marketing cessation (discontinuation)

Opinion/decision on a Paediatric investigation plan (PIP): Rezzayo, rezafungin acetate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0343/2024

Submitted by Anonymous (not verified) on 3 July 2026 - 8:00

Opinion/decision on a Paediatric investigation plan (PIP): Rezzayo, rezafungin acetate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0343/2024

Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, PIP number: P/0028/2023

Submitted by Anonymous (not verified) on 3 July 2026 - 7:30

Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, PIP number: P/0028/2023

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More